massimo broggini
Mario Negri Institute for Pharmacological Research (IRCCS)
Milano, Italy
Specialty Chief Editor
Cancer Molecular Targets and Therapeutics
- Frontiers in Oncology
- Cancer Molecular Targets and Therapeutics
- Editorial Board
Type at least 3 characters
665 editors
Shape the future of research in your field
Join the board
Editors
Specialty Chief Editors
Associate Editors
brian d adams
Brain Institute of America
New Haven, United States
Associate Editor
Cancer Molecular Targets and Therapeutics
nemat ali
King Saud University
Riyadh, Saudi Arabia
Associate Editor
Cancer Molecular Targets and Therapeutics
christina m. annunziata
National Cancer Institute (NIH)
Rockville, United States
Associate Editor
Cancer Molecular Targets and Therapeutics
robert d arnold
Auburn University
Auburn, United States
Associate Editor
Cancer Molecular Targets and Therapeutics
samir attoub
United Arab Emirates University
Al-Ain, United Arab Emirates
Associate Editor
Cancer Molecular Targets and Therapeutics
maria laura avantaggiati
Georgetown University
Washington, United States
Associate Editor
Cancer Molecular Targets and Therapeutics
abdel kareem azab
University of Texas Southwestern Medical Center
Dallas, United States
Associate Editor
Cancer Molecular Targets and Therapeutics
dalia barsyte-lovejoy
University of Toronto
Toronto, Canada
Associate Editor
Cancer Molecular Targets and Therapeutics
ioana berindan neagoe
University of Medicine and Pharmacy Iuliu Hatieganu
Cluj-Napoca, Romania
Associate Editor
Cancer Molecular Targets and Therapeutics
donald bottaro
Center for Cancer Research, National Cancer Institute (NIH)
Bethesda, United States
Associate Editor
Cancer Molecular Targets and Therapeutics
jonathan brody
Thomas Jefferson University
Philadelphia, United States
Associate Editor
Cancer Molecular Targets and Therapeutics
mans broekgaarden
Institut National de la Santé et de la Recherche Médicale (INSERM)
Paris, France
Associate Editor
Cancer Molecular Targets and Therapeutics
harry burke
Uniformed Services University of the Health Sciences
Bethesda, United States
Associate Editor
Cancer Molecular Targets and Therapeutics
george calin
University of Texas MD Anderson Cancer Center
Houston, United States
Associate Editor
Cancer Molecular Targets and Therapeutics